365 related articles for article (PubMed ID: 28620302)
1. Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel.
Kanters TA; Stevanovic J; Huys I; Vulto AG; Simoens S
Front Pharmacol; 2017; 8():322. PubMed ID: 28620302
[No Abstract] [Full Text] [Related]
2. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.
Jha A; Upton A; Dunlop WC; Akehurst R
Adv Ther; 2015 Aug; 32(8):742-56. PubMed ID: 26343027
[TBL] [Abstract][Full Text] [Related]
3. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.
Aladul MI; Fitzpatrick RW; Chapman SR
Res Social Adm Pharm; 2019 Mar; 15(3):310-317. PubMed ID: 29807834
[TBL] [Abstract][Full Text] [Related]
4. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.
Brodszky V; Baji P; Balogh O; Péntek M
Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S65-71. PubMed ID: 24832837
[TBL] [Abstract][Full Text] [Related]
5. Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries.
Yoo HK; Byun HG; Caprioli F; Fumery M; Peyrin-Biroulet L; Sreedhar S; Potter J; Jang M
BMC Health Serv Res; 2022 Nov; 22(1):1319. PubMed ID: 36333704
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country.
Mezones-Holguin E; Gamboa-Cardenas RV; Sanchez-Felix G; Chávez-Corrales J; Helguero-Santin LM; Laban Seminario LM; Burela-Prado PA; Castro-Reyes MM; Fiestas F
Front Pharmacol; 2019; 10():1010. PubMed ID: 31798442
[No Abstract] [Full Text] [Related]
8. The nocebo effect challenges the non-medical infliximab switch in practice.
Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
[TBL] [Abstract][Full Text] [Related]
9. Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
Kim Y; Kwon HY; Godman B; Moorkens E; Simoens S; Bae S
Front Pharmacol; 2020; 11():970. PubMed ID: 32733238
[TBL] [Abstract][Full Text] [Related]
10. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
[TBL] [Abstract][Full Text] [Related]
11. A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.
Brodszky V; Rencz F; Péntek M; Baji P; Lakatos PL; Gulácsi L
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):119-25. PubMed ID: 26162458
[TBL] [Abstract][Full Text] [Related]
12. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.
Manova M; Savova A; Vasileva M; Terezova S; Kamusheva M; Grekova D; Petkova V; Petrova G
Front Pharmacol; 2018; 9():1070. PubMed ID: 30294275
[TBL] [Abstract][Full Text] [Related]
13. Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019.
García-Goñi M; Río-Álvarez I; Carcedo D; Villacampa A
Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33918795
[TBL] [Abstract][Full Text] [Related]
14. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
McClean AR; Cheng L; Bansback N; Clement F; Tadrous M; Harrison M; Law MR
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):2011-2021. PubMed ID: 36752358
[TBL] [Abstract][Full Text] [Related]
15. Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France.
Oppe M; Muresan B; Chan K; Radu X; Schultz BG; Turpin RS; Nucit A; Fenu E
Expert Rev Pharmacoecon Outcomes Res; 2023 Feb; 23(2):205-213. PubMed ID: 36541707
[TBL] [Abstract][Full Text] [Related]
16. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
[TBL] [Abstract][Full Text] [Related]
17. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
[TBL] [Abstract][Full Text] [Related]
18. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting.
Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
BioDrugs; 2019 Jun; 33(3):285-297. PubMed ID: 30945207
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
